The combination of low-dose non-cytotoxic gemcitabine with SRA737 plus anti–PD-L1 increased the expression of type I IFN genes and chemokines (CCL5 and CXCL10), and the number of CD8, dendritic cells, and M1 macrophages in the tumor microenvironment. The gene discussed is CD8A; the disease is neoplasm.